4.11.0 Dementia
Donepezil
Donepezil 10mg orodispersible tablets sugar free
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Donepezil 10mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Donepezil 5mg orodispersible tablets sugar free
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Donepezil 5mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Galantamine
Galantamine 16mg modified-release capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Galantamine 24mg modified-release capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Galantamine 8mg modified-release capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Memantine
Memantine 10mg orodispersible tablets sugar free
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Memantine 10mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Memantine 10mg/ml oral solution sugar free
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Memantine 20mg orodispersible tablets sugar free
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Memantine 20mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Memantine 5mg/10mg/15mg/20mg tablets treatment initiation pack
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine
Rivastigmine 1.5mg capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine 13.3mg/24hours transdermal patches
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine 3mg capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine 4.5mg capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine 4.6mg/24hours transdermal patches
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine 6mg capsules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |
Rivastigmine 9.5mg/24hours transdermal patches
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Central nervous system | Dementia with Lewy bodies |
| Central nervous system | Dementia associated with Parkinson's disease |
| Central nervous system | Alzheimer’s disease |